查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1403438

製藥建模軟體市場至2030年的預測：按組件、部署、作業系統、公司規模、採購模式、應用程式、最終用戶和地區的全球分析

Drug Modeling Software Market Forecasts to 2030 - Global Analysis By Component, By Deployment, Operating System, Enterprise Size, Purchasing Model, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球製藥建模軟體市場規模將達到 77 億美元，預計到2030年將達到 155 億美元，預測期內年複合成長率為 10.5%。

藥物建模軟體是指採用演算法和模擬來預測、分析和最佳化藥物發現和藥物研發方面的計算工具。這些程序有助於理解分子交互作用、藥物動力學和藥物-標靶相互作用。對生物系統、化學結構和藥物行為進行模擬和建模有助於設計、篩檢和最佳化潛在的候選藥物，並提高藥物研發過程的效率和成功率。

據美國研究和製藥工業協會表示，成功的藥物研發平均花費 26 億美元。

新療法的需求不斷成長

隨著複雜疾病的流行和治療要求的不斷變化，對創新和有效治療方法的需求日益成長。藥物建模軟體可以探索和預測模擬不同的分子結構，促進潛在候選藥物的識別和最佳化。這種技術主導的方法不僅加速了藥物研發過程，而且還支持客製化治療方法的設計，滿足更精確、更有針對性和更有效的治療方法的需求，支持軟體在促進醫療保健創新方面的重要性和廣泛使用。

檢驗和準確性挑戰

確保預測模型的準確性和可靠性需要對實驗資料進行廣泛的驗證，這通常需要大量的時間和資源。此外，複雜的生物系統以及藥物和標靶之間的多樣化交互作用會影響軟體的預測能力，並導致準確性挑戰。準確再現現實世界複雜性的限制阻礙了軟體的有效性，需要不斷的改進和檢驗工作。

人們對雲端基礎的分析和資料處理越來越感興趣

雲端平台提供了可擴展、經濟高效的基礎設施，可以處理龐大的資料集和複雜的運算。這種轉變可以實現更好的協作、更快的處理速度以及更佳存取高階建模工具。此外，雲端基礎的解決方案有助於與其他應用程式無縫整合，並實現全球研究人員之間的即時資料共用。擁抱這一趨勢不僅可以簡化工作流程，還可以促進創新，使組織能夠利用最尖端科技並最佳化成本和資源利用率，同時推動藥物研發發現和開發的進步。

資料隱私和安全問題

對資料隱私和安全的擔憂對藥物建模軟體市場構成了重大威脅。藥物開發中患者資料和專有資訊的敏感性引起了人們對潛在違規、未授權存取和資料濫用的擔憂。安全缺陷可能會削弱信任，影響採用率，並破壞製藥公司和軟體供應商之間的合作。此外，GDPR 和 HIPAA 等嚴格法規對醫療保健資料的處理施加了嚴格的標準，這加大了軟體開發人員確保合規性的壓力。

COVID-19 的影響：

COVID-19 大流行加速了藥物建模軟體的採用，並加強了其在遠端藥物開發和虛擬臨床試驗中的作用。這增加了對快速藥物設計和重新利用的預測分析和計算方法的依賴，促進對新出現的健康危機的快速反應。然而，研究和臨床活動的中斷暫時影響了市場成長。而這場大流行凸顯了軟體的重要性，刺激了創新並加強了其在敏捷和遠端藥物開發過程中的關鍵作用。

在預測期內，醫院和醫療保健提供者行業預計將是最大的。

由於利用先進軟體進行個體化治療策略，藥物療效預測和治療最佳化的趨勢不斷增強，醫院和醫療保健提供者領域預計將引領藥物建模軟體市場。致力於精準醫療的醫院和醫療保健提供者依靠藥物建模軟體來提供臨床決策支持，以改善患者的治療效果。此外，將這些工具整合到電子健康記錄中有助於無縫實施，有助於在該領域佔據主導地位。

預測期內，藥物研發和開發領域預計年複合成長率最高

由於對新治療藥物的需求持續激增，藥物研發發現和開發領域預計將顯著成長。藥物開發商越來越依賴先進的建模軟體來快速識別、設計和最佳化潛在的候選藥物。此外，人工智慧和機器學習的整合進一步提高了效率，推動了製藥建模軟體市場這一細分市場的顯著成長預測。

佔有率最大的地區

由於強大的製藥和生物技術領域，北美預計將引領製藥建模軟體市場。該地區擁有大量研發投資，先進的醫療基礎設施以及主要行業參與者。此外，該地區對創新和技術採用的重視，以及對個人化醫療和精準藥物開發的高需求，也推動了先進建模軟體的使用。這些因素，加上支持性的法律規範和早期採用新技術的文化，使北美在藥物建模軟體市場中處於主導地位。

年複合成長率最高的地區：

由於製藥和生物技術行業的快速成長以及研發投資的增加，預計亞太地區的製藥建模軟體市場將顯著成長。此外，大量臨床試驗患者群的存在以及對精準醫療的日益關注也推動了藥物建模軟體的採用。此外，擴大醫療基礎設施、技術進步和政府支援措施推動該地區的成長。

提供免費客製化：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球製藥建模軟體市場：依組成部分

  • 軟體
  • 資料庫

第6章 全球製藥建模軟體市場：依部署分類

  • 雲端基礎
  • 混合基地
  • 本地

第7章 全球製藥建模軟體市場：按作業系統

  • Windows
  • Linux
  • Mac Os
  • 其他作業系統

第8章 全球製藥建模軟體市場：依公司規模

  • 主要企業
  • 中小企業

第9章 全球製藥建模軟體市場：依購買模式分類

  • 基於訂閱
  • 一次許可證

第10章 全球製藥建模軟體市場：依應用分類

  • 細胞模擬
  • 化學資訊學
  • 疾病建模
  • 藥物研發發現與開發
  • 基因序列分析
  • 圖形分子建模
  • 醫療圖像
  • 蛋白質建模
  • 其他用途

第11章 全球製藥建模軟體市場：依最終用戶分類

  • 合約研究組織（CRO）
  • 製藥和生物技術公司
  • 醫院和醫療保健提供者
  • 其他最終用戶

第10章 全球製藥建模軟體市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Acellera
  • Biovia
  • Certara
  • Chemical Computing Group
  • Collaborative Drug Discovery, Inc.
  • Cresset
  • Genedata AG
  • Insilico Medicine
  • Instinctools GmbH
  • Leadscope, Inc.
  • Molecular Networks GmbH
  • Nimbus Therapeutics
  • Numerate, Inc.
  • OpenEye Scientific Software
  • Optibrium Ltd.
  • Pharmacelera
  • Physiomics plc
  • Schrodinger, Inc.
  • Simulations Plus, Inc.
Product Code: SMRC24663

According to Stratistics MRC, the Global Drug Modeling Software Market is accounted for $7.7 billion in 2023 and is expected to reach $15.5 billion by 2030 growing at a CAGR of 10.5% during the forecast period Drug Modeling Software refers to computational tools employing algorithms and simulations to predict, analyze and optimize aspects of drug discovery and development. These programs facilitate the understanding of molecular interactions, pharmacokinetics and drug-target interactions. By simulating and modeling biological systems, chemical structures and drug behavior, they aid in designing, screening and optimizing potential drug candidates, enhancing the efficiency and success rates of pharmaceutical research and development processes.

According to the Pharmaceutical Research and Manufacturers of America, a successful drug's research and development cost an average of US$2.6 BN.

Market Dynamics:

Driver:

Growing need for novel treatments

With an increasing prevalence of complex diseases and evolving therapeutic requirements, there's a pressing need for innovative and effective treatments. Drug modeling software enables the exploration of diverse molecular structures and predictive simulations, expediting the identification and optimization of potential drug candidates. This technology-driven approach not only accelerates the discovery process but also aids in designing tailored therapies, meeting the demand for more precise, targeted and efficacious treatments, consequently propelling the software's significance and adoption in advancing healthcare innovation.

Restraint:

Validation and precision challenges

Ensuring the accuracy and reliability of predictive models requires extensive validation against experimental data, often demanding substantial time and resources. Additionally, complex biological systems and the diverse interactions between drugs and targets contribute to precision challenges, impacting the software's predictive capabilities. The limitations of accurately replicating real-world complexities hinder the software's effectiveness, necessitating continuous refinement and validation efforts.

Opportunity:

Rising interest in cloud-based analytics and data processing

Cloud platforms offer scalable, cost-effective infrastructure capable of handling vast datasets and complex computations. This shift allows for enhanced collaboration, faster processing speeds and greater accessibility to sophisticated modeling tools. Moreover, cloud-based solutions facilitate seamless integration with other applications and enable real-time data sharing among researchers globally. Embracing this trend not only streamlines workflows but also fosters innovation, empowering organizations to leverage cutting-edge technologies and drive advancements in drug discovery and development while optimizing costs and resource utilization.

Threat:

Data privacy and security concerns  

Data privacy and security concerns pose a significant threat to the drug modeling software market. The sensitive nature of patient data and proprietary information in drug development raises apprehensions about potential breaches, unauthorized access or data misuse. Instances of security lapses could erode trust, impact adoption rates, and hinder collaboration between pharmaceutical entities and software providers. Moreover, stringent regulations like GDPR and HIPAA impose rigorous standards for handling healthcare data, augmenting the pressure on software developers to ensure compliance.

COVID-19 Impact:

The COVID-19 pandemic accelerated the adoption of drug modeling software, intensifying its role in remote drug development and virtual clinical trials. It prompted a heightened reliance on predictive analytics and computational methods for rapid drug design and repurposing, facilitating faster responses to emerging health crises. However, disruptions in research and clinical activities temporarily affected market growth. Yet, the pandemic underscored the software's criticality, spurring innovation and reinforcing its pivotal role in agile and remote drug development processes.

The hospitals & healthcare providers segment is expected to be the largest during the forecast period

The hospitals and healthcare providers segment is anticipated to lead the drug modeling software market due to its increasing leverage of advanced software for personalized treatment strategies, drug efficacy predictions and treatment optimization. With a focus on precision medicine, hospitals and healthcare providers utilize drug modeling software for clinical decision support, enhancing patient care outcomes. Additionally, the integration of these tools into electronic health records facilitates seamless implementation, contributing to the segment's dominance.

The drug discovery and development segment is expected to have the highest CAGR during the forecast period

The drug discovery and development segment is poised for significant growth owing to the continuous surge in demand for novel therapeutics. Drug developers increasingly rely on advanced modeling software to expedite the identification, design and optimization of potential drug candidates. Additionally, the integration of artificial intelligence and machine learning further enhances efficiency, driving the substantial anticipated growth of this segment within the drug modeling software market.

Region with largest share:

North America is anticipated to lead the drug modeling software market due to its robust pharmaceutical and biotech sectors. The region boasts significant R&D investments, advanced healthcare infrastructure and a strong presence of major industry players. Moreover, the region's emphasis on innovation and technology adoption, coupled with a high demand for personalized medicine and precision drug development, drives the use of sophisticated modeling software. These factors, combined with supportive regulatory frameworks and a culture of early adoption of novel technologies, position North America to dominate the drug modeling software market.

Region with highest CAGR:

Asia Pacific is poised for substantial growth in the drug modeling software market due to the region's burgeoning pharmaceutical and biotech industries, coupled with increasing R&D investments. Additionally, the presence of a vast patient pool for clinical trials and a growing emphasis on precision medicine foster the adoption of drug modeling software. Moreover, expanding healthcare infrastructure, technological advancements and supportive government initiatives propel growth in this region.

Key players in the market:

Some of the key players in drug modeling software market include Acellera, Biovia, Certara, Chemical Computing Group, Collaborative Drug Discovery, Inc., Cresset, Genedata AG, Insilico Medicine, Instinctools GmbH, Leadscope, Inc., Molecular Networks GmbH, Nimbus Therapeutics, Numerate, Inc., OpenEye Scientific Software, Optibrium Ltd., Pharmacelera, Physiomics plc, Schrodinger, Inc. and Simulations Plus, Inc.

Key Developments:

In May 2023, Cresset announced the latest release of molecular modeling platform that delivers improved efficiencies for small molecule discovery therefore Flare V7. This helps the organisation developing more revenue.

In May 2023, Fujitsu launched the Biodrug Design Accelerator platform to increase peptide drug discovery research. This platform helps peptide drug discovery scientists in pharmaceutical industries to speed up and increases the efficiency of peptide drug development, especially through the cycles "design, make, test, analyze" (DMTA), ultimately allowing faster and informed design of peptide drug candidates and effective communication among scientists about synthesis and testing.

In February 2023, Accenture has made a strategic investment, through Accenture Ventures, in Ocean Genomics, a technology and AI company that has developed advanced computational platforms to assist biopharma companies to discover and develop more effective diagnostics and therapeutics.

Components Covered:

  • Software
  • Database

Deployments Covered:

  • Cloud Based
  • Hybrid-Based
  • On-Premises

Operating Systems Covered:

  • Windows
  • Linux
  • Mac Os
  • Other Operating Systems

Enterprise Sizes Covered:

  • Large Enterprise Size
  • Small & Medium Enterprise Size

Purchasing Models Covered:

  • Subscription Based
  • One-Time License

Applications Covered:

  • Cellular Simulation
  • Cheminformatics
  • Disease Modeling
  • Drug Discovery and Development
  • Gene Sequence Analysis
  • Graphical Molecular Modeling
  • Medical Imaging
  • Protein Modeling
  • Other Applications

End Users Covered:

  • Contract Research Organizations (CROs)
  • Pharmaceutical & Biotechnology Companies
  • Hospitals & Healthcare Providers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Drug Modeling Software Market, By Component

  • 5.1 Introduction
  • 5.2 Software
  • 5.3 Database

6 Global Drug Modeling Software Market, By Deployment

  • 6.1 Introduction
  • 6.2 Cloud Based
  • 6.3 Hybrid-Based
  • 6.4 On-Premises

7 Global Drug Modeling Software Market, By Operating System

  • 7.1 Introduction
  • 7.2 Windows
  • 7.3 Linux
  • 7.4 Mac Os
  • 7.5 Other Operating Systems

8 Global Drug Modeling Software Market, By Enterprise Size

  • 8.1 Introduction
  • 8.2 Large Enterprise Size
  • 8.3 Small & Medium Enterprise Size

9 Global Drug Modeling Software Market, By Purchasing Model

  • 9.1 Introduction
  • 9.2 Subscription Based
  • 9.3 One-Time License

10 Global Drug Modeling Software Market, By Application

  • 10.1 Introduction
  • 10.2 Cellular Simulation
  • 10.3 Cheminformatics
  • 10.4 Disease Modeling
  • 10.5 Drug Discovery and Development
  • 10.6 Gene Sequence Analysis
  • 10.7 Graphical Molecular Modeling
  • 10.8 Medical Imaging
  • 10.9 Protein Modeling
  • 10.10 Other Applications

11 Global Drug Modeling Software Market, By End User

  • 11.1 Introduction
  • 11.2 Contract Research Organizations (CROs)
  • 11.3 Pharmaceutical & Biotechnology Companies
  • 11.4 Hospitals & Healthcare Providers
  • 11.5 Other End Users

10 Global Drug Modeling Software Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Acellera
  • 12.2 Biovia
  • 12.3 Certara
  • 12.4 Chemical Computing Group
  • 12.5 Collaborative Drug Discovery, Inc.
  • 12.6 Cresset
  • 12.7 Genedata AG
  • 12.8 Insilico Medicine
  • 12.9 Instinctools GmbH
  • 12.10 Leadscope, Inc.
  • 12.11 Molecular Networks GmbH
  • 12.12 Nimbus Therapeutics
  • 12.13 Numerate, Inc.
  • 12.14 OpenEye Scientific Software
  • 12.15 Optibrium Ltd.
  • 12.16 Pharmacelera
  • 12.17 Physiomics plc
  • 12.18 Schrodinger, Inc.
  • 12.19 Simulations Plus, Inc.

List of Tables

  • Table 1 Global Drug Modeling Software Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Drug Modeling Software Market Outlook, By Component (2021-2030) ($MN)
  • Table 3 Global Drug Modeling Software Market Outlook, By Software (2021-2030) ($MN)
  • Table 4 Global Drug Modeling Software Market Outlook, By Database (2021-2030) ($MN)
  • Table 5 Global Drug Modeling Software Market Outlook, By Deployment (2021-2030) ($MN)
  • Table 6 Global Drug Modeling Software Market Outlook, By Cloud Based (2021-2030) ($MN)
  • Table 7 Global Drug Modeling Software Market Outlook, By Hybrid-Based (2021-2030) ($MN)
  • Table 8 Global Drug Modeling Software Market Outlook, By On-Premises (2021-2030) ($MN)
  • Table 9 Global Drug Modeling Software Market Outlook, By Operating System (2021-2030) ($MN)
  • Table 10 Global Drug Modeling Software Market Outlook, By Windows (2021-2030) ($MN)
  • Table 11 Global Drug Modeling Software Market Outlook, By Linux (2021-2030) ($MN)
  • Table 12 Global Drug Modeling Software Market Outlook, By Mac Os (2021-2030) ($MN)
  • Table 13 Global Drug Modeling Software Market Outlook, By Other Operating Systems (2021-2030) ($MN)
  • Table 14 Global Drug Modeling Software Market Outlook, By Enterprise Size (2021-2030) ($MN)
  • Table 15 Global Drug Modeling Software Market Outlook, By Large Enterprise Size (2021-2030) ($MN)
  • Table 16 Global Drug Modeling Software Market Outlook, By Small & Medium Enterprise Size (2021-2030) ($MN)
  • Table 17 Global Drug Modeling Software Market Outlook, By Purchasing Model (2021-2030) ($MN)
  • Table 18 Global Drug Modeling Software Market Outlook, By Subscription Based (2021-2030) ($MN)
  • Table 19 Global Drug Modeling Software Market Outlook, By One-Time License (2021-2030) ($MN)
  • Table 20 Global Drug Modeling Software Market Outlook, By Application (2021-2030) ($MN)
  • Table 21 Global Drug Modeling Software Market Outlook, By Cellular Simulation (2021-2030) ($MN)
  • Table 22 Global Drug Modeling Software Market Outlook, By Cheminformatics (2021-2030) ($MN)
  • Table 23 Global Drug Modeling Software Market Outlook, By Disease Modeling (2021-2030) ($MN)
  • Table 24 Global Drug Modeling Software Market Outlook, By Drug Discovery and Development (2021-2030) ($MN)
  • Table 25 Global Drug Modeling Software Market Outlook, By Gene Sequence Analysis (2021-2030) ($MN)
  • Table 26 Global Drug Modeling Software Market Outlook, By Graphical Molecular Modeling (2021-2030) ($MN)
  • Table 27 Global Drug Modeling Software Market Outlook, By Medical Imaging (2021-2030) ($MN)
  • Table 28 Global Drug Modeling Software Market Outlook, By Protein Modeling (2021-2030) ($MN)
  • Table 29 Global Drug Modeling Software Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 30 Global Drug Modeling Software Market Outlook, By End User (2021-2030) ($MN)
  • Table 31 Global Drug Modeling Software Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
  • Table 32 Global Drug Modeling Software Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 33 Global Drug Modeling Software Market Outlook, By Hospitals & Healthcare Providers (2021-2030) ($MN)
  • Table 34 Global Drug Modeling Software Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.